Patents by Inventor Avinash Muppidi

Avinash Muppidi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein tyrosine-tyrosine analogs and methods of using the same
    Patent number: 11820803
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: November 21, 2023
    Assignee: Eli Lilly and Company
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
    Publication number: 20220112255
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • Neuregulin-4 compounds and methods of use
    Patent number: 11242370
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20220025009
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • Protein tyrosine-tyrosine analogs and methods of using the same
    Patent number: 11155592
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 26, 2021
    Assignee: Eli Lilly and Company
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • Modified therapeutic agents and compositions thereof
    Patent number: 10987427
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: April 27, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Peter G. Schultz, Avinash Muppidi, Insha Ahmad, Pengyu Yang
  • NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
    Publication number: 20200354421
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: March 31, 2020
    Publication date: November 12, 2020
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei NI, James David Pancook
  • PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20200140514
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 7, 2020
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20190328888
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Application
    Filed: May 7, 2019
    Publication date: October 31, 2019
    Inventors: Weijun SHEN, Peter G. SCHULTZ, Avinash MUPPIDI, Insha AHMAD, Pengyu YANG
  • Modified therapeutic agents and compositions thereof
    Patent number: 10286078
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: May 14, 2019
    Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Peter G. Schultz, Avinash Muppidi, Insha Ahmad, Pengyu Yang
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20180207276
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents comprising a half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 26, 2018
    Inventors: Weijun SHEN, Avinash MUPPIDI, Peter G. SCHULTZ
  • Oxyntomodulin analogs and methods of making and using same
    Patent number: 9931379
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 3, 2018
    Assignees: The Research Foundation for The State University of New York, California Institute for Biomedical Research
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME
    Publication number: 20170196940
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 13, 2017
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20160287713
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Application
    Filed: September 12, 2014
    Publication date: October 6, 2016
    Inventors: Weijun SHEN, Peter G. SCHULTZ, Avinash MUPPIDI, Andreas CRAMERI, Insha AHMAD, Pengyu YANG
  • Cross-linked peptides and proteins, methods of making same, and uses thereof
    Patent number: 9029332
    Abstract: Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene aryl cross-linking moieties. Compositions comprising the cross-linked proteins and peptides can be used as pharmaceutical delivery formulations. The cross-linked proteins and peptides can have improved properties, such as cell permeability, as compared to the parent protein or peptide.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 12, 2015
    Assignee: The Research Foundation for The State University of New York
    Inventors: Qing Lin, Avinash Muppidi
  • Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof
    Publication number: 20140057857
    Abstract: Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene aryl cross-linking moieties. Compositions comprising the cross-linked proteins and peptides can be used as pharmaceutical delivery formulations. The cross-linked proteins and peptides can have improved properties, such as cell permeability, as compared to the parent protein or peptide.
    Type: Application
    Filed: December 15, 2011
    Publication date: February 27, 2014
    Applicant: The Research Foundation for the State University of New York
    Inventors: Qing Lin, Avinash Muppidi